# ARTEMIDE-01: HCP commentary report

> 53 verified statements (10 from clinicians verified by NPI or staff page) from 15 commentary sources · 7 findings · updated Oct 29, 2026

## Report

- Trial: Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
- NCT ID: NCT04995523
- Registry: https://clinicaltrials.gov/study/NCT04995523
- Sponsor: AstraZeneca
- Phase: Phase 1/Phase 2
- Status: Active, not recruiting
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 43024ca6008463773f95cd085826a83041f65fa13b62aff9ddd40a8c8ffd2339

## Counts

- HCP commentary sources screened: 32
- Sources cited by verified statements: 16
- Verified statements: 53
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 10
- Findings: 7
- People found in screened sources: 10
- Voices cited: 10
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 4

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on ARTEMIDE-01 in the sources reviewed for this edition leads to one open question: What confirmatory evidence would establish clinically meaningful, PD-L1-specific benefit while resolving post-CPI activity and TIGIT-class doubts? Its leading findings: (1) the favorable CPI-naive reading is concentrated in PD-L1-high disease and remains provisional. (2) low post-CPI response activity receives sharply different interpretations. (3) whether rilvegostomig can validate TIGIT remains an explicit controversy. 4 more findings follow. 32 sources screened, 16 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What confirmatory evidence would establish clinically meaningful, PD-L1-specific benefit while resolving post-CPI activity and TIGIT-class doubts?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The favorable CPI-naive reading is concentrated in PD-L1-high disease and remains provisional
- F2. Low post-CPI response activity receives sharply different interpretations
- F3. Whether rilvegostomig can validate TIGIT remains an explicit controversy
- F4. Cooperative binding and reduced Fc activity are proposed explanations, not demonstrated clinical advantages
- F5. Favorable safety language requires cohort-specific severity and uncertainty
- F6. A speaker’s methodological endorsement concerns efficient dose selection, not comparative efficacy
- F7. The patient-facing eligibility summary leaves prior-immunotherapy requirements unresolved

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 5 | 6 | 5 | 4 | recorded | 2 |
| F2 | 7 | 8 | 5 | 4 | recorded | 3 |
| F3 | 6 | 4 | 4 | 4 | recorded | 3 |
| F4 | 9 | 5 | 3 | 2 | none recorded | 3 |
| F5 | 7 | 9 | 5 | 4 | none recorded | 2 |
| F6 | 6 | 6 | 2 | 1 | none recorded | 3 |
| F7 | 4 | 3 | 2 | 0 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 0 | 0 | 0 | 1 | 6 | 0 | 4 posts and articles, 1 publication | yes |
| F2 | 4 | 0 | 0 | 2 | 1 | 7 | 1 | 4 posts and articles, 1 publication | yes |
| F3 | 2 | 3 | 0 | 0 | 1 | 6 | 0 | 4 posts and articles | yes |
| F4 | 4 | 0 | 0 | 3 | 2 | 9 | 0 | 2 posts and articles, 1 publication | yes |
| F5 | 6 | 0 | 0 | 0 | 1 | 7 | 3 | 4 posts and articles, 1 publication | yes |
| F6 | 5 | 0 | 0 | 0 | 1 | 7 | 1 | 1 post or article, 1 publication | yes |
| F7 | 0 | 0 | 0 | 0 | 4 | 5 | 0 | 1 podcast or video, 1 publication | yes |

### Trial dimensions

- Primary endpoint: Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters: F1 (1 shared claims), F2 (2 shared claims), F5 (4 shared claims)
- Primary endpoint: Rate of rilvegostomig discontinuation due to toxicity: no finding draws on it directly
- Primary endpoint: Objective Response Rate (ORR): F1 (2 shared claims), F2 (1 shared claims), F5 (1 shared claims)
- Secondary endpoints: F1 (3 shared claims), F2 (1 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Population and setting: F1 (4 shared claims), F2 (3 shared claims), F5 (2 shared claims), F7 (2 shared claims)
- The comparison: F7 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (2 shared claims), F5 (4 shared claims)
- Design and conduct: F6 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 53 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 16 | Counts free |
| Speaker attribution for cited voices | 10 | Paid |

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters | discussed | 5 | 5 |
| Primary endpoint: Rate of rilvegostomig discontinuation due to toxicity | no commentary found | 0 | 0 |
| Primary endpoint: Objective Response Rate (ORR) | discussed | 4 | 3 |
| Secondary endpoints | discussed | 6 | 5 |
| Population and setting | discussed | 9 | 8 |
| The comparison | discussed | 1 | 1 |
| Safety and tolerability | discussed | 5 | 5 |
| Design and conduct | discussed | 2 | 1 |
| TIGIT viability and proposed bispecific/Fc differentiation | discussed | 9 | 6 |
| Interpretation of the 2023 AZD2936/rilvegostomig response pattern | discussed | 5 | 4 |
| Further Phase III and ADC-combination development versus established clinical use | discussed | 3 | 3 |
| Organizational enthusiasm and ownership of reported views | discussed | 4 | 3 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 27 | 13 |
| Bluesky threads | 3 | 0 |
| LinkedIn posts | 1 | 1 |
| YouTube | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-06-04 to 2026-10-26
- Cited window: 2023-06-04 to 2026-08-14
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
- Registry: NCT04995523 (https://clinicaltrials.gov/study/NCT04995523)
- Study IDs: D7020C00001 · 2023-508262-15-00 (EU CT Number) · 2021-000857-23
- Sponsor: AstraZeneca
- Design: Phase 1/Phase 2 · interventional, non randomized, sequential, phase1, phase2
- Status: Active, not recruiting
- Enrollment: 212 (actual)
- Start: 2021-09-14 (actual)
- Primary completion: 2026-08-28 (estimated)
- Primary endpoint: Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters (Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig)
- Primary endpoint: Rate of rilvegostomig discontinuation due to toxicity (Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months))
- Primary endpoint: Objective Response Rate (ORR) (Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years))
- Intervention: AZD2936 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 2 matching sources (2 X threads) could not be read and are not included.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are a limited and uneven sample of public discussion; source totals and reposts cannot be interpreted as independent-HCP counts or the prevalence of a view.
- Some potentially relevant public posts were unavailable or incompletely assessed. Discussion that did not use recognizable trial or drug names may be missing.
- Several named authors’ clinical roles are not established. Source descriptions of credentials or trial involvement do not independently verify clinical qualifications or make trial-associated views external assessments.
- The results publication reports CPI-experienced parts A and B. CPI-naive efficacy figures in this report are presented as the figures cited by the relevant commentators, not as findings established by that publication.
- Comments from different meetings, post dates, treatment-exposure settings and data cutoffs cannot establish a change of mind or a direct efficacy comparison.
- The patient-facing video leaves contradictory prior-immunotherapy requirements unexplained and does not establish a current arm count.
- A standalone protocol and an exact AZD2936 regulatory label were not available; no regulatory position is inferred.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (53 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/artemide-01-nct04995523
- Agents: POST https://www.erudio.com/api/orders with {"report": "artemide-01-nct04995523", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=artemide-01-04995523

## Cite

Erudio Health. ARTEMIDE-01 (NCT04995523): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/artemide-01-nct04995523

## Machine access

- JSON: https://www.erudio.com/reports/artemide-01-nct04995523.json
- Markdown: https://www.erudio.com/reports/artemide-01-nct04995523.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "artemide-01-04995523"}`